- Home
- LZ vs NRIX Comparison
LZ vs NRIX Comparison
Compare LZ & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LZ | NRIX |
|---|---|---|
| Founded | 2001 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LZ | NRIX |
|---|---|---|
| Price | $8.77 | $18.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | $11.50 | ★ $29.08 |
| AVG Volume (30 Days) | ★ 1.9M | 1.2M |
| Earning Date | 02-25-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $727,483,000.00 | $83,687,000.00 |
| Revenue This Year | $13.38 | $59.40 |
| Revenue Next Year | $7.07 | N/A |
| P/E Ratio | $74.00 | ★ N/A |
| Revenue Growth | 7.17 | ★ 48.32 |
| 52 Week Low | $6.47 | $8.18 |
| 52 Week High | $12.40 | $22.50 |
Technical Indicators
Market Signals| Indicator | LZ | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 35.66 | 52.54 |
| Support Level | $8.38 | $18.12 |
| Resistance Level | $10.51 | $20.18 |
| Average True Range (ATR) | 0.39 | 1.04 |
| MACD | -0.16 | -0.08 |
| Stochastic Oscillator | 20.83 | 55.83 |
Price Performance
Historical ComparisonAbout LZ LegalZoom.com Inc.
LegalZoom.com Inc is an online provider of services that meet the legal needs of small businesses and consumers in the United States. The company also offers services that include ongoing compliance and tax advice and filings, business licenses, accounting, virtual mailbox and e-signature solutions, trademark filings, and estate plans.
About NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.